Integra LifeSciences Holdings Corporation (IART), a medical technology company, Thursday reported net loss of $484.07 million or $6.31 per share for the second quarter, significantly higher than $12.40 million or $0.16 per share loss in the same quarter a year ago, primary due to a goodwill impairment charge of $511.37 million.
Excluding one-time items, the company posted adjusted earnings of $34.37 million or $0.45 per share, down from $49.01 million or $0.63 per share in the prior year.
On average, 10 analysts expected earnings of $0.43 per share. Analysts' estimates typically exclude special items.
Operating loss widened to $512.67 million from $3.03 million loss last year.
Adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization decreased to $71.22 million from $83.76 million a year ago.
Revenue for the quarter slightly declined to $415.61 million from $418.18 million in the previous year. The consensus estimate was for $395.06 million.
For the third quarter, the company expects revenues to be in the range of $410 million to $420 million, a growth of 7.7% - 10.3%. Adjusted EPS is expected between $0.40 and $0.45. Analysts expect the company to report earnings of $0.58 per share on revenue of $418.83 million.
For the full year, Integra LifeSciences is updating its revenue guidance to $1.655 billion - $1.680 billion form the previous $1.650 billion - $1.715 billion. It has confirmed its adjusted EPS outlook of $2.19 - $2.29. The Street is looking for earnings of $2.24 per share with revenue of $1.67 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.